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Background: We sought to evaluate the incidence and clinical impact of luteinizing hormone (LH) rises prior to
and during gonadotropin-releasing hormone (GnRH) antagonist treatment started on day 5 or 6 of ovarian
stimulation with recombinant follicle-stimulating hormone (rFSH).
Methods: Pooled data from three trials with the GnRH antagonist ganirelix started on day 5 (n = 961) and from five
trials with ganirelix started on day 6 (n = 1135) of ovarian stimulation with rFSH were retrospectively analyzed.
Results: The incidence of LH rises (LH ≥ 10.0 IU/L) prior to ganirelix treatment was 2.3% and 6.6% on ganirelix start days
5 and 6, respectively (P < 0.01). During ganirelix treatment this incidence was 1.2% and 2.3%, respectively (P = 0.06).
Women with LH rise on day 5 or 6 had a higher ovarian response with more oocytes recovered, mean ± SD, 12.9 ± 8.5
versus no LH rise, 10.2 ± 6.4 (P < 0.01). In women with and without LH rise prior to ganirelix treatment the ongoing
pregnancy rates were similar (26.0% vs 29.9%; odds ratio [OR], 0.89; 95% confidence interval [CI], 0.55-1.44).
Women with LH rise during ganirelix treatment had a lower ovarian response with 7.5 ± 6.7 oocytes recovered
versus no LH rise, 10.2 ± 6.4 (P = 0.02) and a tendancy for a lower chance of ongoing pregnancy (16.7% vs
29.9%; OR, 0.52; 95% CI, 0.21-1.26).
Conclusions: The incidence of early and late LH rises was low but may be further reduced by initiating ganirelix
on stimulation day 5 rather than on day 6. In contrast to women with an early LH rise, women with a late LH
rise may have a reduced chance of ongoing pregnancy.
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In the early follicular phase of the natural cycle, high
follicle-stimulating hormone (FSH) concentrations initi-
ate follicular development, which leads to rising serum
estradiol concentrations. This, in turn, causes a negative
feedback in FSH release from the pituitary, resulting in
atresia of the smaller follicles and selection of a single
dominant follicle. Once serum estradiol concentrations
surpass a certain level, a positive feedback loop stimu-
lates the pituitary and results in the preovulatory
luteinizing hormone (LH) surge. This LH surge is* Correspondence: jfrattarelli@armghawaii.com
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reproduction in any medium, provided the orresponsible for final oocyte maturation and subsequent
ovulation [1].
During induced multiple follicular development, when
FSH concentrations are maintained because of exogen-
ous gonadotropin administration, natural selection of a
single dominant follicle does not occur and multiple fol-
licles continue to grow. This increased number of folli-
cles produces higher serum estradiol concentrations and
consequently, the serum estradiol concentration that
triggers the preovulatory LH surge is reached prema-
turely, i.e., before the follicles have fully developed. For
successful assisted reproduction treatment, it is essential
to prevent premature luteinization and ovulation. Without
intervention, premature luteinization occurs in about 25%
of ovarian stimulation cycles, leading to cycle cancellational Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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luteinization may have an unfavorable impact on oo-
cyte quality, fertilization, and implantation. Use of a
gonadotropin-releasing hormone (GnRH) agonist [4]
or antagonist [5] has been shown to improve the repro-
ductive outcome of ovarian stimulation by preventing pre-
mature LH surges.
GnRH antagonists first became available for the pre-
vention of premature endogenous LH surges in women
undergoing ovarian stimulation a decade ago. However,
late LH rises occasionally occur in women during GnRH
antagonist treatment, sometimes due to drug noncom-
pliance [6] or possibly due to increased endogenous
GnRH release in response to rising serum estradiol con-
centrations. If these LH rises are considerable and occur
with premature progesterone (P) rises, ovulation be-
comes imminent.
Women with induced multifollicular development may
also have an early LH rise prior to the start of the GnRH
antagonist; this is more frequently observed in high re-
sponders. In earlier clinical studies, the GnRH antagonist
ganirelix was often fixed to start on stimulation day 6;
however, in high ovarian responders it may be preferred
to start ganirelix treatment on day 5 to lower the inci-
dence of early LH rises. The latter is determined by the
study population, the gonadotropin of choice, and the
FSH starting dose. The incidence of early LH rises on
day 6 of stimulation prior to the first ganirelix adminis-
tration was 15% when the starting dose of recombinant
FSH (rFSH) was 225 IU [7] and 4.3% when the starting
dose of rFSH was 150 IU [8]. The present study was
undertaken to evaluate the incidence of LH rises and
their clinical impact when occurring prior to ganirelix
treatment started on either day 5 or 6 or during ganirelix
treatment in more than 2000 patients following ovarian
stimulation with recombinant FSH.
Methods
Clinical trials with ganirelix started on day 5 of ovarian
stimulation
Individual patient data were pooled from three multi-
center, randomized clinical trials with a fixed ganirelix
(Ganirelix Acetate Injection, Orgalutran, N.V. Orga-
non, The Netherlands) treatment (0.25 mg/d) start on
the morning of day 5. All three trials were primarily
designed to show efficacy and safety of corifollitropin
alfa in ovarian stimulation versus rFSH. Only informa-
tion obtained from the rFSH reference arms of these
three trials was included in this analysis.
i. The corifollitropin alfa dose-finding study - a phase
2 open-label trial comprising three corifollitropin
alfa treatment groups and an rFSH reference group
[9]. Women aged 20–39 years with a body massindex (BMI) of 17–31 kg/m2 received a fixed daily
dose of 150 IU rFSH from cycle days 2 or 3 up to
the day of human chorionic gonadotropin (hCG)
administration (N = 82).
ii. Engage - a phase 3 double-blind efficacy and safety
study that compared 150 μg corifollitropin alfa with
daily 200 IU rFSH [10]. Women aged 18–36 years
with a BMI of 18–32 kg/m2 received a fixed daily
dose of 200 IU rFSH up to and including the day of
hCG administration (N = 750).
iii. Ensure - a phase 3 double-blind efficacy and safety
study that compared 100 μg corifollitropin alfa with
daily 150 IU rFSH [11]. Women aged 18–36 years
with a BMI of 18–32 kg/m2 received a fixed daily
dose of 150 IU rFSH up to and including the day of
hCG administration (N = 129).
Clinical trials with ganirelix started on day 6 of ovarian
stimulation
Individual patient data from five clinical trials with a
fixed ganirelix start on the morning of day 6 of ovarian
stimulation with rFSH were pooled. Only data using the
approved dose of ganirelix (0.25 mg/d up to the day of
hCG administration) were used for the analyses.
i-iii. Three pivotal phase 3 randomized controlled
trials to assess the efficacy, safety, and tolerability
of ganirelix. Women aged 18–39 years with a BMI
of 18–29 kg/m2 received daily rFSH from
stimulation day 1 up to the day of hCG
administration, with dose adjustment as necessary
after stimulation day 6.– Start dose of rFSH 150 IU/d, N = 462 [8]
– Start dose of rFSH 225 IU/d, N = 197 [7]
– Start dose of rFSH 150 IU/d, N = 226 [12].
iv. A single-center, open-label phase 3 safety trial
undertaken in Israel between March 1998 and July
1999 [13], start dose of rFSH 150 IU/d, N = 167.
v. A multicenter, open-label, randomized,
pharmacokinetic and pharmacodynamic study
carried out between December 2000 and November
2001 [14], start dose of rFSH 150 IU/day, N = 83.
Assessments
The size and number of follicles was measured by ultra-
sound scan.
Validated immunoassays were performed to measure
serum concentrations of LH, estradiol, and P. In all trials (ex-
cept the North American Ganirelix Study) these measure-
ments were carried out by one central laboratory (Waltrop,
Germany) using a time-resolved fluoroimmunoassay
(AutoDelfia immunofluorometric assay, PerkinElmer
Life and Analytical Sciences, Brussels, Belgium). De-
tection limits for serum LH, estradiol, and P were 0.6 IU/L,
Table 1 Demographic and baseline characteristics
Ganirelix started
on day 5 (n = 961)
Ganirelix started
on day 6 (n = 1135)
Age, y, mean ± SD 31.5 ± 3.3 31.4 ± 4.1
Body weight, kg, mean ± SD 66.2 ± 8.6 63.5 ± 10.2
BMI, kg/m2, mean ± SD 24.1 ± 3.0 23.4 ± 3.3
Region, %
North America 41.9 17.4
Asia 5.9 0
Middle East 0 24.4
Europe 52.1 58.2
Duration of infertility, y,
mean ± SD
3.2 ± 2.2 4.6 ± 3.2
Primary infertility, % 54.0 57.8
Cause of infertility*, %
Male factor 47.7 51.9
Tubal factor 24.3 32.2
Endometriosis 14.0 8.7
Cervical mucus problems 0.6 1.2
Unexplained infertility 28.8 13.7
Other 6.0 4.1
BMI body mass index, SD standard deviation.
*A patient could have more than one cause of infertility.
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the North American Ganirelix Study, serum LH concen-
trations were measured by the Immulite 1000 LH assay
(DPC, Los Angeles, CA) and estradiol and P concentra-
tions at a central laboratory (Quest Diagnostics, USA).
LH rise prior to and during ganirelix treatment was
defined as serum LH ≥10 IU/L and P rise was defined as
serum P ≥3.18 nmol/L (1 ng/mL).
Statistical analysis
Individual patient data from trials in which ganirelix was
started on stimulation day 5 were pooled (N = 961) and,
separately, the data from trials in which ganirelix was
started on day 6 were pooled (N = 1135) as if the data
were from one large trial. The data used in the current
analyses reflect minor corrections to the number of oo-
cytes retrieved previously published in the Engage [10]
and Ensure [11] trial data.
Descriptive statistics of demographic, baseline, and
treatment characteristics were presented by start day
of ganirelix treatment (day 5, day 6).
The incidence of LH rises with or without P rises prior to
ganirelix treatment (early rises) and during ganirelix treat-
ment (late rises) were presented by start day of ganirelix
treatment. The incidences between day 5 and day 6 ganirelix
start were compared and tested using a Fisher's exact test.
As the overall incidence of LH rises is low, individual
patient data from all trials were pooled (N = 2096) to ex-
plore the effect of early and late LH rises on estradiol
concentrations, number of follicles and oocytes, and on-
going pregnancy rates.
Direct comparisons for the ovarian response and on-
going pregnancy rates between women with an LH rise
prior to and during ganirelix treatment and women who
had no LH rise were performed and included all trials
for both groups. However, such comparison was not
performed for subjects who started ganirelix on day 5
and on day 6 because these data sets were from different
clinical trials conducted during different time periods
and in different geographic regions, which may affect
these clinical outcomes [15].
Analysis of variance (ANOVA) was applied to estimate
the effect of early and late LH rises on the number of
follicles ≥11 mm on day of hCG and on the number of
oocytes retrieved, respectively. Factor trial was included
as an independent factor (covariate) in the ANOVA
model to adjust for trial effects. The effect of LH rise on
the median estradiol concentrations was estimated using
the Wilcoxon rank sum test. Logistic regression analysis
was applied to estimate the odds ratio (OR) for ongoing
pregnancy between women with early LH rise and no
LH rise and between women with late LH rise and no
LH rise, respectively. Trial was included as a covariate in
the logistic model.Results
Patient demographic and baseline characteristics
This analysis included 2096 women who started stimula-
tion on cycle day 2 or 3; 961 of these women started
ganirelix treatment on stimulation day 5 and 1135
started ganirelix treatment on stimulation day 6. The
demographic and baseline characteristics for these women
are given in Table 1. Women who started ganirelix treat-
ment at stimulation day 5 had a similar age, body weight,
and BMI as patients who started ganirelix treatment at
stimulation day 6. The mean (±SD) age of women with an
LH rise prior to ganirelix treatment or with an LH rise
during ganirelix treatment, or without any LH rise was
31.8 ± 3.7, 31.4 ± 3.8, and 31.5 ± 3.8, respectively. Women
who started ganirelix treatment at stimulation day 5 or 6
had the same infertility history although their geographic
regions were clearly different.
Treatment details
The median duration of ganirelix treatment was 5.0 days
both for women who started ganirelix treatment on
stimulation day 5 and for women who started treatment
on stimulation day 6 (percentiles P5, P95: 3.0, 7.0 for
start day 5, and 2.0, 9.0 for start day 6). Women who
started ganirelix on day 5 received most frequently a
daily starting dose of 200 IU rFSH (78%) whereas
women who started ganirelix on day 6, received most
frequently a daily starting dose of 150 IU rFSH (69%).
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duration of stimulation was shorter, leading to a similar
overall amount of rFSH used in both groups. The me-
dian (P5, P95) total dose of rFSH was 1600 IU (1200,
2200) and 1575 IU (1050, 3000) in the group starting
day 5 and day 6, respectively.Incidence of LH rise
The incidence of LH rises measured at stimulation day 5
or 6 prior to the start of ganirelix treatment (early LH
rises) and during ganirelix treatment (late LH rises) is
presented in Table 2.
The incidence of early LH rises was 2.3% (95% confi-
dence interval [CI], 1.4-3.4) in women who started
ganirelix treatment on stimulation day 5 and 6.6% (95%
CI, 5.2-8.2) in women who started ganirelix on stimula-
tion day 6 (P < 0.01). The incidence of early LH rises
with concomitant P rises on days 5 and 6 was 1.0% (95%
CI, 0.5-1.9) and 2.0% (95% CI, 1.2-2.9), respectively.
The incidence of late LH rises in women who started
ganirelix treatment at stimulation day 5 was 1.2% (95%
CI, 0.6-2.0) and in women who started ganirelix at
stimulation day 6 was 2.3% (95% CI, 1.4-3.3) (P = 0.06).
The incidence of late LH rises with concomitant P rises
on days 5 and 6 was 0.5% (95% CI, 0.2-1.2) and 0.9%
(95% CI, 0.4-1.6), respectively.Table 2 Incidence of LH rises (≥10 IU/L) and of LH rises
with P rises (≥3.18 nmol/L) measured at stimulation day
5 or 6 prior to the start of ganirelix treatment and during
ganirelix treatment
Ganirelix start day % (95% CI), n/N P value*
LH rises Early Day 5 2.3 (1.4-3.4) < 0.01
22/955
Day 6 6.6 (5.2-8.2)
74/1113
Late Day 5 1.2 (0.6-2.0) 0.06
11/949
Day 6 2.3 (1.4-3.3)
25/1096
LH+P rises Early Day 5 1.0 (0.5-1.9) 0.11
10/955
Day 6 2.0 (1.2-2.9)
22/1113
Late Day 5 0.5 (0.2-1.2) 0.44
5/949
Day 6 0.9 (0.4-1.6)
10/1096
Early indicates on start day of ganirelix treatment; Late indicates during
ganirelix treatment. CI confidence intervals, LH luteinizing hormone,
P progesterone. *Day 5 versus day 6.Ovarian response according to LH rise
Table 3 shows the ovarian response in women with early
LH rise, late LH rise, and no LH rise. Five subjects had
an early and a late LH rise. Women with an early LH
rise prior to ganirelix treatment had a higher mean num-
ber of follicles ≥11 mm on the day of hCG than women
without an LH rise (P < 0.01). Accordingly, their median
serum estradiol concentration on the day of hCG was
also higher.
Women with a late LH rise during ganirelix treat-
ment had a lower mean number of growing follicles on
the day of hCG administration than women without an
LH rise (P = 0.01). Their median estradiol concentra-
tion was not significantly different from those with no
LH rise (P = 0.38).
Clinical outcome according to LH rise
Table 3 shows the clinical outcome in women with early
LH rise, late LH rise, and no LH rise. In women with an
early LH rise prior to ganirelix treatment more oocytes
were retrieved compared with women without an LH
rise (P < 0.01). The ongoing pregnancy rate following
fresh embryo transfer was similar in women with an
early LH rise and no LH rise. The estimated odds ratio
(OR [95% CI]) for ongoing pregnancy, adjusted for trial
effect, for women with an early LH rise versus women
without an LH rise was 0.89 (0.55-1.44).
In women with a late LH rise during ganirelix treat-
ment, fewer oocytes were retrieved compared with
women without an LH rise (P = 0.02). The ongoing
pregnancy rate following fresh embryo transfer was nu-
merically lower in women with a late LH rise than in
those with no LH rise. The estimated OR (95% CI) for
ongoing pregnancy, adjusted for trial effect, for women
with a late LH rise versus women without an LH rise
was 0.52 (0.21-1.26). In total, 15 women had an LH and
P rise during ganirelix treatment and five of these 15
women still became pregnant.
Discussion
This retrospective pooled analysis indicates that the inci-
dence of early and late LH rises prior to and during
ganirelix treatment is low and comparison of the clinical
outcome shows that, in contrast to women with an early
LH rise, women with a late LH rise may have a reduced
chance of ongoing pregnancy.
The incidence of LH rises on stimulation day 5 was
significantly lower than on day 6 and the incidence dur-
ing ganirelix treatment tended to be lower in subjects
who started treatment on day 5 rather than on day 6, in-
dicating that an earlier initiation of ganirelix treatment
may further lower the incidence during ganirelix treat-
ment as observed in this study. The limitation of the
retrospective approach of this study is acknowledged.
Table 3 Ovarian response and clinical outcome according to early or late LH rise versus no LH rises
Early LH rises (n = 96) Late LH rises (n = 36) No LH rises (n = 1962)
Follicles ≥11 mm on day of hCG, mean ± SD 13.2 ± 7.8 8.9 ± 6.6 11.6 ± 6.1
Serum estradiol on day of hCG, pmol/L, median (P5, P95) 7303 (3171, 16478) 5391 (573, 15047) 4367 (1369, 10955)
Oocytes retrieved, mean ± SD 12.9 ± 8.5 7.5 ± 6.7 10.2 ± 6.4
Ongoing pregnancy rate, % 26.0 16.7 29.9
hCG human chorionic gonadotropin, P5, P95 5th and 95th percentiles, SD standard deviation.
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age age; thus, it may be difficult to predict which women
will have an increased risk for a premature LH rise. Pre-
diction of ovarian response may be facilitated by pre-
treatment assessment of the antral follicle count and of
anti-Müllerian hormone, both of which have been shown
to be reliable predictors of ovarian response [16,17].
When women start ovarian stimulation with a relatively
high dose of rFSH they may subsequently present with
more follicles and higher serum estradiol concentrations
during the early follicular phase, thereby reaching the
threshold for LH surge earlier during stimulation. In a
previous study in which women were treated with a
fixed starting dose of 225 IU FSH, employment of an algo-
rithm of criteria to prevent premature LH surges resulted
in GnRH antagonist initiation earlier than stimulation day
6 in two thirds of patients (138/208 initiated on days 4
or 5). This earlier start resulted in an improved clinical
outcome [18].
In contrast to previous publications that have reported
premature LH peaks in up to 22% of subjects during
(mild) stimulation while treated with a GnRH antagonist
[19-21], the current analysis indicates that LH rise prior
to and during ganirelix treatment is a comparatively in-
frequent event in women aged up to 39 years with regu-
lar menstrual cycles undergoing ovarian stimulation
prior to in vitro fertilization or intracytoplasmic sperm
injection. In addition, the incidence of a concomitant
rise in P was even lower, which for the early LH rises
may be related to the low number of LH receptors dur-
ing the first days of stimulation [22].
While women with an early LH rise prior to ganirelix
treatment had higher numbers of oocytes retrieved com-
pared with women without an LH rise, the impact of this
early LH rise seems limited as the chance of ongoing
pregnancy was not compromised. This may be explained
by a possible short-lived pulse of LH rather than a precur-
sor to luteinization and premature ovulation. In contrast,
women with a late LH rise during ganirelix treatment had
a lower ovarian response and had a lower chance of on-
going pregnancy, though the OR for ongoing pregnancy
for women with an LH rise versus women without LH rise
was not significant. Some of these LH rises may have been
caused by drug noncompliance; however, these cannot bedocumented because ganirelix concentrations were not
measured during these trials. Other LH rises may indeed
be related to either premature luteinization or a low ovar-
ian response, and the causes require further investigation.
While a daily dose of 0.25 mg ganirelix has been dem-
onstrated to be an effective dose to prevent premature
LH rises during multiple follicular development in
in vitro fertilization cycles, there is some evidence that a
GnRH antagonist is less effective in blocking the positive
feedback effect of estradiol in women with mild or
nonstimulated ovaries [23,24]; this is in agreement with
the lower ovarian response of women with an LH rise
during ganirelix treatment in the current retrospective
analysis. The cause of these LH rises remains to be eluci-
dated but it has been suggested that a reduced produc-
tion of gonadotropin surge-attenuating factor may be
involved, which is hypersecreted in the case of induced
multiple follicular development [23].
Late LH rises during GnRH antagonist treatment
lower the chance of pregnancy and may be further re-
duced by starting antagonist treatment timely. These re-
sults support a flexible regimen of starting ganirelix
treatment on day 5 or day 6 of stimulation, depending
on the ovarian response.Conclusions
This combined retrospective analysis indicates that the
incidence of LH rises prior to and during ganirelix treat-
ment is low and may be further reduced by initiating
ganirelix on ovarian stimulation day 5 rather than on
day 6. An early LH rise prior to ganirelix treatment may
occur more frequently in women with a relatively high
ovarian response, whereas a late LH rise during ganirelix
treatment occurs most commonly in women with a nor-
mal to low ovarian response. In contrast to women with
an early LH rise, women with a late LH rise may have a
reduced chance of ongoing pregnancy.
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